19 - 20 May 2021
11th Annual Vaccines World Summit 2021
Virtual
Don't Miss Out on Vaccines World Summit 2021
500+
High Profile Attendees
50+
Organizations
50+
Expert Speakers
2+
Days of Networking
The Concept
Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025. The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.
Vaccines World Summit, for developing economies aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration.
Conference Agenda
11th Annual Vaccines World Summit 2021 brings together the entire vaccines industry value chain including international and local vaccine players, government health authorities, regulators, academics & research institutions and solution providers to share knowledge, grow networks and form partnerships. Take your first step towards entrenching yourself within the vaccines community, get your copy of the brochure!
Register Now!
2021 Speakers
Rajinder Kumar Suri DCVMN
CEODCVMNRajinder Kumar Suri joined DCVMN (Developing Countries Vaccine Manufacturers Network) as CEO w.e.f. Jan 15th, 2021. Before this, he was donning the hat of Chief Executive-Biologicals, Panacea Biotec Ltd. Rajinder has over 40 years of rich experience in Pharmaceuticals & Biological products in Indian & International markets out of which over 24 years’ experience at the top management level including four years on the Board of Directors of the Indian subsidiary of Sanofi Pasteur. The remaining 19 years were with Pharma out of which 16 years with Lupin. Mr. Suri brings with him over 3 years of consulting experience as CEO & Senior Advisor, Arete Business Advisors.
Rajinder has been Member-Policy & Planning Committee (PPC), an advisory body to GAVI Board, representing DCVMN from October 2013 till June 2017, as also a Member of the GAVI Steering Committee for Supply & Procurement Strategy. He has played a lead role in negotiations & interactions with the Ministry of Health, Government of India, UN agencies, and other Global organizations like WHO, UNICEF, Bill & Melinda Gates Foundation, Clinton Health Access Initiative & several others. Rajinder is also a former Member Executive Committee & Vice-President, DCVMN for a period of two years from Oct. 2014 - 2016.
Matthew Downham CEPI
Sustainable Manufacturing LeadCEPIUnited KingdomDr. Downham studied a Bachelor of Sciences degree (with honors) in industrial biology at London South Bank Polytechnic (UK) which included a placement with Boehringer Mannheim (DE). He then completed a Ph.D. in biochemical engineering (Birmingham University, UK), a post-doctoral research fellowship - bio-molecular sciences (Liverpool John Moores University, UK), and a post-graduate certificate in further/higher education
(Bolton Institute, UK). He joined the biopharmaceutical industry in 1997 and has worked for Protherics (UK), Bavarian Nordic & Morphosys (DE), Novartis Vaccines & Diagnostics (IT) & AstraZeneca (UK).
Dr. Downham worked on the preclinical and early clinical development of a vaccine, antibody, or enzyme therapies for infectious, hypertension, inflammatory, and oncology indications. He was a European Registered Toxicologist (2010-18); Chair, Vaccines Europe Influenza working group (2017-20); Treasurer, International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply task force (2017-20); Vice-Chair, IFPMA Convention on Biological Diversity working group (2018-20).
Dr. Downham has also co-authored 29 publications/abstracts and 3 international patents and in January 2021, joined the Coalition for Epidemic Preparedness Innovations (UK) as the Sustainable Manufacturing Lead.
Key Relevant Information:
BSc Hons Industrial Biology (London South Bank Polytechnic, UK & Boehringer Mannheim, DE), Ph.D. Biochemical Engineering (Birmingham University, UK), PGCE (Bolton Institute, UK), post-doctoral research fellowship – biomolecular sciences (Liverpool John Moores University, UK) and an EU Registered Toxicologist (Royal Society of Biology UK, 2010-‘18) 25 years international biopharmaceutical industry: Boehringer Mannheim (DE), Protherics (UK), Bavarian Nordic & Morphosys (DE), Novartis Vaccines & Diagnostics (IT), AstraZeneca (UK).
Ashish Sahai Serum Institute of India
Additional DirectorSerum Institute of IndiaIndia
Etleva Kadilli UNICEF
Director, Supply DivisionUNICEFCopenhagen, DenmarkEtleva (Eva) Kadilli is Director of UNICEF’s Supply Division, based in Copenhagen, Denmark, and oversees UNICEF's global supply chain functions with an annual expenditure exceeding USD 3.8 billion. In this capacity, she leads the effective, efficient, and ethical provision of essential and emergency supplies for children, through direct UNICEF programs, and in cooperation with national governments and partners.
Responsible for the management of UNICEF’s supply response to humanitarian crises, Ms. Kadilli is presently leading the organization’s strategic procurement and logistics emergency response to the COVID-19 pandemic. In this capacity, she represents UNICEF in the UN COVID Supply Chain Task Force and also represents the organization in a number of other global forums, including interagency engagements on UN procurement reform, and an alternate member of the Board of Gavi, the Vaccine Alliance. Ms. Kadilli also sits on Gavi’s Audit and Finance Committee, and Market Sensitive Decisions Committee.
A UNICEF staff member for nearly 25 years, Ms. Kadilli has held several roles at the headquarters and field levels, as well as in development and emergency contexts, including Albania, the Democratic Republic of the Congo (DRC), The Gambia, and Somalia. Ms. Kadilli has been with UNICEF’s Supply Division since 2011, where she previously held the position of Deputy Director, Supply Chain, overseeing teams responsible for contracting policy and procedures, quality assurance, global logistics operations, and emergency response. Her other roles have included Chief of Contracting, responsible for procurement oversight and compliance; and Contract Manager and Medical Unit Team Leader for health technology supplies in support of MNCH and HIV/AIDS programs, including during the 2014-2016 Ebola outbreak.
Raches Ella Bharat Biotech
Project Lead: SARS-CoV-2 VaccineBharat BiotechIndia
Dr. Anh Wartel International Vaccine Institute
Deputy Director General, CAREInternational Vaccine InstituteKorea Dr. T. Anh Wartel has 20 years of experience in epidemiological studies, clinical research from phase I to phase IV studies, and CTD development. She earned her MD at the Paris XII Medical School, France, and completed a post-graduate diploma in Public Health from the University of Liverpool, UK. She has extensive experience in the fields of epidemiological and clinical research within both academia and the pharmaceutical industry during her 15 year-long career with Sanofi Pasteur before joining IVI in 2018. After having started her research career as a co-investigator in drugs and therapeutic vaccine trials in HIV infected patients at the French National Agency of Research on HIV/AIDS (ANRS) at Kremlin Bicetre University Hospital in Paris, she then joined Sanofi Pasteur in 2003. Her responsibilities grew over the course of 15 years to include Epidemiology and Clinical R&D activities (e.g., Japanese encephalitis, Pneumococcal Disease, Dengue Disease); Medical Affairs activities as the Regional Medical Expert for enteric, endemic, and travelers vaccines (e.g., rabies, cholera, typhoid fever, hepatitis A, yellow fever, dengue, Japanese encephalitis vaccines); and Country Medical Head for Vietnam and Cambodia. She joined IVI in September of 2018 as the Head of Clinical Development and Regulatory.
Ofer Levy Boston Children's Hospital, Harvard Medical School
Director, Precision Vaccines Program, Division of Infectious DiseasesBoston Children's Hospital, Harvard Medical SchoolUSADr. Ofer Levy was born to and raised by the artist Benjamin Levy and music composer Hannah Levy in New York City, where he graduated from the Bronx High School of Science. After graduating from Yale College (B.S., Molecular Biophysics and Biochemistry), Dr. Levy entered the Medical Scientist (MD/Ph.D.) Training Program at New York University School of Medicine. There he earned his Ph.D. under the mentorship of Drs. Peter Elsbach and Jerrold Weiss, characterizing white blood cell (neutrophil)-derived antimicrobial proteins and peptides. Inspired by his wife Sharon’s example, he chose Pediatrics and completed both residency and fellowship (Infectious Diseases) at Boston Children’s Hospital. He is currently a Professor at Harvard Medical School as well as principal investigator, staff physician, and the Director of the Precisions Vaccine Program in the Division of Infectious Diseases, Boston Children’s Hospital.
The Precision Vaccines Program (PVP) is a platform to foster international collaboration between academia, government, and industry for the development of vaccine formulations optimized to protect vulnerable populations. The PVP is focused on modeling vaccine-induced human immune responses in vitro using a variety of platforms including three-dimensional microphysiologic systems as well as global molecular (“OMIC”) approaches to accelerate and de-risk development of vaccines optimized for populations with distinct immune responses, including those at the extremes of age who suffer the most infections.
He currently leads several NIH/NIAID-supported studies: (a) an Adjuvant Discovery Program contract, leveraging robotic and immunologic approaches to discover, characterize, and formulate novel small molecule adjuvants that may enhance vaccine responses of the young and the elderly; (b) an international Human Immunology Project Consortium effort employing systems biology to define biomarkers of neonatal vaccine immunogenicity, and (c) a number of coronavirus/COVID-related studies including a national effort to discover biomarkers of COVID disease severity as well as a project to discover and develop novel coronavirus vaccines. He lives in Cambridge, Massachusetts along with his wife Dr. Sharon Levy, and their three children.
Scots Roberts Altimmune
Chief Scientific OfficerAltimmuneUSADr. Scot Roberts has served as the Chief Scientific Officer (CSO) for Altimmune since December 2012. He has over two decades of experience managing scientific operations in the fields of cancer and infectious disease and has led drug development efforts for small molecules and biologics with a focus on viral vectors and antiviral therapies. Previously, as CSO for ImQuest BioSciences, Inc., he led scientific operations and business development initiatives. Prior to ImQuest, he held leadership positions at Wellstat Biologics Corporation including Director, Research and Development where he was responsible for the development of biological candidates in oncology including a clinical-stage asset. Dr. Roberts completed a post-doctoral fellowship at the National Cancer Institute, Laboratory of Molecular Virology, and received his Ph.D. from the Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences. Dr. Roberts has authored numerous publications and is an inventor on a broad portfolio of patents.
Arun Kumar CEPI
Preclinical Vaccines Development LeadCEPINorwayDr. Arun Kumar is the Preclinical Vaccines Development Lead at the Coalition for Epidemic Preparedness Innovation (CEPI), Oslo, Norway. The main objective of CEPI is to accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. Dr. Kumar previously held positions at the GlaxoSmithKline Vaccines & Novartis Vaccines and Diagnostics, where he worked on the universal influenza vaccine development program based on Self-amplifying messenger RNA technology. He has focused his career on the next-generation platform technologies for vaccine development and translational sciences. At CEPI, he currently leading global programs including preclinical development, Systems Immunology and also co-leading the CEPI Centralized Global Laboratory Network. He also manages various International collaborative activities. Arun holds a Ph.D. in Immunology and Infectious diseases from the University of Helsinki, Finland.
Remko Van Leeuwen INDIGO
Project CoordinatorINDIGONetherlands
Li Shi Shanghai Zerun Biotechnology
CEOShanghai Zerun BiotechnologyChina
Dr. Farshad Guirakhoo COVAXX and VAXXINITY
Chief Scientific OfficerCOVAXX and VAXXINITYUSA
Kapil Maithil Zydus Cadila
President & Head, Vaccines and DiagnosticsZydus CadilaIndia
Dr. Vickneshwaran Muthu Disease Control Division Ministry of Health, Malaysia
Senior Principal Assistant DirectorDisease Control Division Ministry of Health, MalaysiaMalaysia
2021 Sponsors
Become a Sponsor!
This event promises to be an opportunity to meet and network with vaccine companies from developed as well as developing countries, industry leaders, regulatory officials, academia, and network. Don't miss out on this opportunity and download the brochure to find out more.
Market Intelligence
Presentation: Development & Commercialization Of An Effective Ebola Virus Vaccine
English 
简体中文 
日本語 
한국어 
繁體中文